313 related articles for article (PubMed ID: 19451445)
21. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.
Murphy CC; Bartholomew LK; Carpentier MY; Bluethmann SM; Vernon SW
Breast Cancer Res Treat; 2012 Jul; 134(2):459-78. PubMed ID: 22689091
[TBL] [Abstract][Full Text] [Related]
22. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
Partridge AH; Wang PS; Winer EP; Avorn J
J Clin Oncol; 2003 Feb; 21(4):602-6. PubMed ID: 12586795
[TBL] [Abstract][Full Text] [Related]
23. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
Ziller V; Kalder M; Albert US; Holzhauer W; Ziller M; Wagner U; Hadji P
Ann Oncol; 2009 Mar; 20(3):431-6. PubMed ID: 19150950
[TBL] [Abstract][Full Text] [Related]
24. Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer.
Yung RL; Hassett MJ; Chen K; Gesten FC; Roohan PJ; Boscoe FP; Sinclair AH; Schymura MJ; Schrag D
J Natl Cancer Inst; 2012 Jul; 104(14):1102-5. PubMed ID: 22773822
[TBL] [Abstract][Full Text] [Related]
25. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain.
Font R; Espinas JA; Barnadas A; Izquierdo A; Galceran J; Saladie F; Marcos-Gragera R; Torrent A; Manchon-Walsh P; Borras JM
Breast Cancer Res Treat; 2019 Jun; 175(3):733-740. PubMed ID: 30887164
[TBL] [Abstract][Full Text] [Related]
26. The Breast Cancer Quality of Care Study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy.
Neugut AI; Hillyer GC; Kushi LH; Lamerato L; Nathanson SD; Ambrosone CB; Bovbjerg DH; Mandelblatt JS; Magai C; Tsai WY; Jacobson JS; Hershman DL
Breast J; 2012; 18(3):203-13. PubMed ID: 22487337
[TBL] [Abstract][Full Text] [Related]
27. 5-year adherence to adjuvant endocrine treatment in Dutch women with early stage breast cancer: A population-based database study (2006-2016).
van den Biggelaar YJPG; Kuiper JG; van der Sangen MJC; Luiten EJT; Siesling S; van Herk-Sukel M; Voogd AC; Mesters I
Breast Dis; 2023; 42(1):331-339. PubMed ID: 37927248
[TBL] [Abstract][Full Text] [Related]
28. Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.
Sheppard VB; Faul LA; Luta G; Clapp JD; Yung RL; Wang JH; Kimmick G; Isaacs C; Tallarico M; Barry WT; Pitcher BN; Hudis C; Winer EP; Cohen HJ; Muss HB; Hurria A; Mandelblatt JS
J Clin Oncol; 2014 Aug; 32(22):2318-27. PubMed ID: 24934786
[TBL] [Abstract][Full Text] [Related]
29. Factors associated with longer endocrine therapy use by South Carolina Medicaid-insured breast cancer survivors.
Bedi JS; Mayo RM; Chen L; Dickes L; Sherrill WW; Jones K
J Oncol Pharm Pract; 2020 Jan; 26(1):36-42. PubMed ID: 30885081
[TBL] [Abstract][Full Text] [Related]
30. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers.
Wu XC; Lund MJ; Kimmick GG; Richardson LC; Sabatino SA; Chen VW; Fleming ST; Morris CR; Huang B; Trentham-Dietz A; Lipscomb J
J Clin Oncol; 2012 Jan; 30(2):142-50. PubMed ID: 22147735
[TBL] [Abstract][Full Text] [Related]
31. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer.
Nekhlyudov L; Li L; Ross-Degnan D; Wagner AK
Breast Cancer Res Treat; 2011 Nov; 130(2):681-9. PubMed ID: 21842245
[TBL] [Abstract][Full Text] [Related]
32. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
Blanchette PS; Lam M; Richard L; Allen B; Shariff SZ; Vandenberg T; Pritchard KI; Chan KKW; Louie AV; Desautels D; Raphael J; Earle CC
Breast Cancer Res Treat; 2020 Jan; 179(1):217-227. PubMed ID: 31571072
[TBL] [Abstract][Full Text] [Related]
34. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
[TBL] [Abstract][Full Text] [Related]
35. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097
[TBL] [Abstract][Full Text] [Related]
36. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
Wigertz A; Ahlgren J; Holmqvist M; Fornander T; Adolfsson J; Lindman H; Bergkvist L; Lambe M
Breast Cancer Res Treat; 2012 May; 133(1):367-73. PubMed ID: 22286315
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer.
Rosenberg SM; Zheng Y; Gelber S; Ruddy KJ; Poorvu P; Sella T; Tamimi RM; Wassermann J; Schapira L; Borges VF; Come S; Peppercorn J; Sepucha KR; Partridge AH
Breast Cancer Res Treat; 2023 Feb; 197(3):547-558. PubMed ID: 36436128
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant radiation therapy alone is associated with improved overall survival compared to hormonal therapy alone in older women with estrogen receptor positive early stage breast cancer.
Jhawar SR; Alpert N; Taioli E; Sayan M; Bazan J; Park KU; Stover D; Cherian M; White J; Haffty B; Ohri N
Cancer Med; 2020 Nov; 9(22):8345-8354. PubMed ID: 32942344
[TBL] [Abstract][Full Text] [Related]
39. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
Eifel P; Axelson JA; Costa J; Crowley J; Curran WJ; Deshler A; Fulton S; Hendricks CB; Kemeny M; Kornblith AB; Louis TA; Markman M; Mayer R; Roter D
J Natl Cancer Inst; 2001 Jul; 93(13):979-89. PubMed ID: 11438563
[TBL] [Abstract][Full Text] [Related]
40. Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I-III breast cancer?
Cahir C; Barron TI; Sharp L; Bennett K
Cancer Causes Control; 2017 Mar; 28(3):215-225. PubMed ID: 28210883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
